StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

by · The Cerbat Gem

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note published on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

Cellectis Price Performance

NASDAQ CLLS opened at $1.97 on Friday. The firm has a market cap of $109.50 million, a P/E ratio of -1.40 and a beta of 3.09. The stock’s 50-day moving average is $2.16 and its two-hundred day moving average is $2.33. Cellectis has a fifty-two week low of $0.96 and a fifty-two week high of $3.77. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92.

Cellectis (NASDAQ:CLLS – Get Free Report) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The firm had revenue of $9.50 million during the quarter, compared to analysts’ expectations of $6.00 million. On average, analysts anticipate that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Long Focus Capital Management LLC grew its stake in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the last quarter. Baillie Gifford & Co. grew its position in Cellectis by 1.3% in the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after purchasing an additional 10,605 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares during the period. First Affirmative Financial Network acquired a new position in shares of Cellectis during the third quarter valued at about $45,000. Finally, XTX Topco Ltd bought a new stake in shares of Cellectis in the second quarter valued at about $29,000. 63.90% of the stock is owned by institutional investors.

About Cellectis

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Further Reading